1. Avinger

    0 Comments Leave a Comment

    1-15 of 100 1 2 3 4 5 6 7 »

    1. Mentioned In 100 Articles

    5. Avinger Announces Successful Treatment of First Patients Globally with Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels

      Explore iR DIRECT Cardiology , Other Business News
      Avinger Announces Successful Treatment of First Patients Globally with Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels
      ...tomy procedure by using an imaging modality called optical coherence tomography, or OCT, that is displayed on Avinger's proprietary Lightbox console. Physicians performing atherectomy with other devices must rely solely ...
      Read Full Article
      Mentions: Avinger Arne G. Schwindt

    11. MICRO-MOLDED Anamorphic Reflector Lens For Image Guided THERAPEUTIC/DIAGNOSTIC Catheters

      Explore patentscope.wipo.int Patents , Probes
      MICRO-MOLDED Anamorphic Reflector Lens For Image Guided THERAPEUTIC/DIAGNOSTIC Catheters
      A catheter system for optical coherence tomography includes an elongate catheter body, an optical fiber in the elongate catheter body, and an anamorphic lens assembly coupled with a distal end of the optical fiber. The optical fiber and the lens assembly are together configured to provide a common path for optical radiation reflected from a target and from a reference interface between the distal end of the optical fiber and ...
      Read Full Article
      Mentions: Manish D. Kulkarni Avinger

    16. Avinger Announces First-in-Patient use of Extended Nosecone Version of Next Generation Pantheris

      Explore Avinger Cardiology , Other Business News
      Avinger Announces First-in-Patient use of Extended Nosecone Version of Next Generation Pantheris
      vinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus Hospital in Mnster, Germany, successfully treated the first three patients with the extended nosecone version of the next generation Pantheris Lumivascular atherectomy system (A400EX). This product is a line extension of the existing next generation platform, with a longer nosecone that enhances ...
      Read Full Article
      Mentions: Avinger Arne G. Schwindt
    17. 1-15 of 100 1 2 3 4 5 6 7 »
  1. Search:

  2. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology

    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents

    3. Technology:

      Broadband Sources, Probes, Tunable Sources

    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks

  4. About Avinger

    Avinger

    Avinger Inc was founded in 2007 by John B. Simpson, Ph.D., M.D., Avinger, Inc. is developing the next generation of catheter-based technologies for the treatment of cardiovascular and peripheral vascular disease, utilizing our core competencies in medical device catheter engineering and intravascular imaging.  Avinger acquired Sawtooth Laboratories  in 2010.

  5. Related Topics

    1. Optical Coherence Tomography For Biological Imaging
      44 articles also mentioned John B. Simpson
    2. Avinger, Inc. Announces Completion of Merger With Sawtooth Labs, Inc.
      41 articles also mentioned FDA
    3. Avinger to Perform Two Live Ocelot Cases at LINC Conference in Leipzig, Germany
      17 articles also mentioned Arne G. Schwindt
    4. Will 2011 be seen as a “Tipping Point” for Industrial Contribution to the Advancement of the Field of Optical Coherence Tomography?
      8 articles also mentioned St. Jude Medical

  6. Quotes about Avinger

    1. The CE Mark approval for Wildcat is a huge step for Avinger and our dedication to helping the millions of afflicted PAD patients worldwide...With the rate of PAD in Europe closely rivaling the U.S., more and more patients are confronted with the threat of amputation and quality-of-life issues resulting from invasive bypass surgery. We are thrilled to be one step closer to our goal of empowering physicians everywhere with the most advanced tools and technologies to perform the least invasive procedures for PAD sufferers around the globe.
      John B. Simpson in Avinger Receives CE Mark Approval for Its Wildcat Catheter for the Treatment of Peripheral Artery Chronic Total Occlusions and Will Present Results from Its Connect Study at EuroPCR Conference May 17-19
    2. Ocelot CE Mark is a long anticipated milestone for Avinger and a much larger milestone for me professionally. I’ve been working on uniting intravascular guidance with therapeutic products for 30 years and I’m humbled that we’ve been able to achieve this at Avinger... This speaks volumes about our team at Avinger and their dedication to patient care. Ocelot CE Mark is a pivotal step that allows us to immediately help more patients suffering from PAD.”
      John B. Simpson in Avinger Receives CE Mark Approval for Its Ocelot Catheter That Incorporates Real-Time Intravascular Guidance Using Optical Coherence Tomography (OCT)
    3. This is a major milestone for Avinger and a true testament to the perseverance of all our employees and investors. Many people said we couldn't do it...Ocelot and CONNECT II is our first step toward incorporating intravascular imaging into therapeutic catheters. We truly believe this will revolutionize the treatment of vascular disease and amputation prevention.
      John B. Simpson in Avinger Enrolls First European PAD Patient in CONNECT II Global Clinical Trial